asfotase alfa

Phase 3

AstraZeneca PLC (AZN)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Hypophosphatasia

RAREBPS804

Phase 2

View Full Landscape

Drug Information

Target Indication

Hypophosphatasia

Clinical Trial

NCT01163149

Last updated: 4/29/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/28/2015

Strensiq

Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AZN

AstraZeneca PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Saruparib (AZD5305)Phase 3

Ovarian Cancer

exenatide twice dailyPhase 3

Type 2 Diabetes Mellitus

AZD1152Phase 3

Acute Myeloid Leukemia

ChemotherapyPhase 3

Anticancer Treatment

Ciclesonide nasalPhase 3

Rhinitis, Allergic, Perennial

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts